News
ITCI
126.89
-0.24%
-0.30
RPT-BREAKINGVIEWS-J&J’s $15 bln depression deal eases pharma blues
Reuters · 15h ago
ITCI Crosses Above Average Analyst Target
NASDAQ · 15h ago
BUZZ-Brokerages downgrade Intra-Cellular after J&J deal
Reuters · 15h ago
Intra-Cellular downgraded to Neutral from Overweight at Piper Sandler
TipRanks · 16h ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $132 FROM $100
Reuters · 22h ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM
Reuters · 22h ago
Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus
Barchart · 23h ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: PIPER SANDLER RAISES TARGET PRICE TO $132 FROM $107
Reuters · 1d ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: PIPER SANDLER CUTS TO NEUTRAL FROM OVERWEIGHT
Reuters · 1d ago
Intra-Cellular downgraded to Market Perform from Outperform at Leerink
TipRanks · 1d ago
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Benzinga · 1d ago
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
TipRanks · 1d ago
Intra-Cellular downgraded to Neutral from Outperform at Baird
TipRanks · 1d ago
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Benzinga · 1d ago
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
Barchart · 1d ago
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
Barchart · 1d ago
J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
TipRanks · 1d ago
BUZZ-Intra-Cellular hits record high on $14.6 billion buyout from J&J
Reuters · 1d ago
Hold Rating Reiterated for Intra-Cellular Therapies Amid Johnson & Johnson Acquisition at $132 per Share
TipRanks · 1d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 1d ago
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.